Evidence map›Paper›PMID 35855324›Full record

ArticleNAR genomics and bioinformatics2022

Ψ-Footprinting approach for the identification of protein synthesis inhibitor producers.

Franziska Handel, Andreas Kulik, Katharina W Wex, Anne Berscheid, Julian S Saur, Anika Winkler, Daniel Wibberg, Jörn Kalinowski, Heike Brötz-Oesterhelt, Yvonne Mast

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Modern Trends in Natural Antibiotic Discovery.Life (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Franziska HandelDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Faculty of Science, University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Andreas KulikDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Faculty of Science, University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Katharina W WexDepartment of Microbial Bioactive Compounds; Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen; Tübingen, Baden-Württemberg 72076, Germany.
Anne BerscheidDepartment of Microbial Bioactive Compounds; Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen; Tübingen, Baden-Württemberg 72076, Germany.
Julian S SaurBiomolecular Chemistry, Institute of Organic Chemistry, University of Tübingen, Tübingen, Baden-Württemberg 72076, Germany.
Anika WinklerCenter for Biotechnology (CeBiTec), Bielefeld University, Universitätsstraße 27, 33615 Bielefeld, Germany.
Daniel WibbergCenter for Biotechnology (CeBiTec), Bielefeld University, Universitätsstraße 27, 33615 Bielefeld, Germany.
Jörn KalinowskiCenter for Biotechnology (CeBiTec), Bielefeld University, Universitätsstraße 27, 33615 Bielefeld, Germany.ORCID https://orcid.org/0000-0002-9052-1998
Heike Brötz-OesterheltDepartment of Microbial Bioactive Compounds; Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen; Tübingen, Baden-Württemberg 72076, Germany.
Yvonne MastDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Faculty of Science, University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.ORCID https://orcid.org/0000-0003-3099-5777

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, one of the biggest challenges in antibiotic research is a targeted prioritization of natural compound producer strains and an efficient dereplication process to avoid undesired rediscovery of already known substances. Thereby, genome sequence-driven mining strategies are often superior to wet-lab experiments because they are generally faster and less resource-intensive. In the current study, we report on the development of a novel

Identifiers

PMID35855324
PMCPMC9290621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.